Coherus BioSciences, Inc. (NASDAQ:CHRS) has a beta value of 1.86 and has seen 995,349 shares traded in the last trading session. The company, currently valued at $1.34 Billion, closed the last trade at $18.71 per share which meant it gained $0.02 on the day or 0.11% during that session. The CHRS stock price is -27.79% off its 52-week high price of $23.91 and 41.96% above the 52-week low of $10.86. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.11 Million shares traded. The 3-month trading volume is 1.04 Million shares.
The consensus among analysts is that Coherus BioSciences, Inc. (CHRS) is a Buy stock at the moment, with a recommendation rating of 1.9. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. 1 out of 10 have rated it as a Hold, with 8 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.4.
Coherus BioSciences, Inc. (NASDAQ:CHRS) trade information
Sporting 0.11% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Sep 10 when the CHRS stock price touched $19.65- or saw a rise of 4.78%. Year-to-date, Coherus BioSciences, Inc. shares have moved 3.92%, while the 5-day performance has seen it change 2.41%. Over the past 30 days, the shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) have changed -1.89%. Short interest in the company has seen 18.58 Million shares shorted with days to cover at 17.87.
Wall Street analysts have a consensus price target for the stock at $30.9, which means that the shares’ value could jump 65.15% from current levels. The projected low price target is $22 while the price target rests at a high of $35. In that case, then, we find that the current price level is +87.07% off the targeted high while a plunge would see the stock lose 17.58% from current levels.
Coherus BioSciences, Inc. (CHRS) estimates and forecasts
Figures show that Coherus BioSciences, Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained +39.73% over the past 6 months, with this year growth rate of 35.77%, compared to 13.7% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -36.5% and -42.9% for the next quarter. Revenue growth from the last financial year stood is estimated to be +38.9%.
8 analysts offering their estimates for the company have set an average revenue estimate of $123.63 Million for the current quarter. 8 have an estimated revenue figure of $121.61 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $101.6 Million and $123.86 Million respectively for this quarter and the next, and analysts expect sales will grow by 21.7% for the current quarter and -1.8% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +16.2% over the past 5 years. Earnings growth for 2020 is a modest +138.1% while over the next 5 years, the company’s earnings are expected to increase by 2.2%.
Coherus BioSciences, Inc. (NASDAQ:CHRS)’s Major holders
Insiders own 3.24% of the company shares, while shares held by institutions stand at 106.2% with a share float percentage of 109.75%. Investors are also buoyed by the number of investors in a company, with Coherus BioSciences, Inc. having a total of 276 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 10.22 Million shares worth more than $182.55 Million. As of June 29, 2020, Blackrock Inc. held 14.3% of shares outstanding.
The other major institutional holder is Temasek Holdings (Private) Limited, with the holding of over 7.38 Million shares as of June 29, 2020. The firm’s total holdings are worth over $131.83 Million and represent 10.33% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Core S&P Smallcap ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. As of June 29, 2020, the former fund manager holds about 5.29% shares in the company for having 3784297 shares of worth $67.59 Million while later fund manager owns 3.19 Million shares of worth $56.93 Million as of June 29, 2020, which makes it owner of about 4.46% of company’s outstanding stock.